KALA BIO, Inc.(KALA)

Biotechnology · Arlington, MA

$0.37+0.00 (+1.24%)

Delayed quote: Oct 6, 2026, 10:04 AM EDT

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T14:07:11.099Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:07:11.099Z.

Quote observation: 2026-10-06T14:04:55.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 7,097,707
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 229,000
TTM operating EBITDA · period ending 2026-06-30: -20,805,000

FMP input reference: 2fde06f259e28fcaf0a0d51df993d991938700e907f86078bced96cac1655d96

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KALA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

KALA Competitors' EV/EBITDA Ratio

KALA

KALA BIO, Inc.

Current

Market Cap

$7.10M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MGRX

Mangoceuticals, Inc.

vs KALA

Market Cap

$7.09M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CURX

Curanex Pharmaceuticals Inc Common Stock

vs KALA

Market Cap

$7.06M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CODX

Co-Diagnostics, Inc.

vs KALA

Market Cap

$6.88M

EV/EBITDA Ratio

N/A

TTM Avg

1.39x

3Y Avg

7.68x

5Y Avg

7.68x

HSCS

HeartSciences Inc.

vs KALA

Market Cap

$7.78M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BOLT

Bolt Biotherapeutics, Inc.

vs KALA

Market Cap

$6.82M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INM

InMed Pharmaceuticals Inc.

vs KALA

Market Cap

$7.31M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACON

Aclarion, Inc.

vs KALA

Market Cap

$6.80M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LGVN

Longeveron Inc.

vs KALA

Market Cap

$7.46M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ENSC

Ensysce Biosciences, Inc.

vs KALA

Market Cap

$6.65M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
KALA BIO, Inc. (KALA)	$7.10M	N/A	N/A	N/A	N/A
Mangoceuticals, Inc. (MGRX)vs ›	$7.09M	N/A	N/A	N/A	N/A
Curanex Pharmaceuticals Inc Common Stock (CURX)vs ›	$7.06M	N/A	N/A	N/A	N/A
Co-Diagnostics, Inc. (CODX)vs ›	$6.88M	N/A	1.39x	7.68x	7.68x
HeartSciences Inc. (HSCS)vs ›	$7.78M	N/A	N/A	N/A	N/A
Bolt Biotherapeutics, Inc. (BOLT)vs ›	$6.82M	N/A	N/A	N/A	N/A
InMed Pharmaceuticals Inc. (INM)vs ›	$7.31M	N/A	N/A	N/A	N/A
Aclarion, Inc. (ACON)vs ›	$6.80M	N/A	N/A	N/A	N/A
Longeveron Inc. (LGVN)vs ›	$7.46M	N/A	N/A	N/A	N/A
Ensysce Biosciences, Inc. (ENSC)vs ›	$6.65M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics